-
1
dPCR enables rapid detection of actionable mutations in cancers.
-
2
TERT and KRAS mutations were successfully validated in tissue samples.
-
3
100% concordance with reference methods was achieved.
-
4
Liquid biopsy applications may enhance early detection of cancer recurrence.
-
5
dPCR assays require minimal DNA input, making them suitable for samples with low quantity or quality.
-
6
The future of oncology diagnostics may rely heavily on dPCR methodologies.
Original Source(s)
Related Content
Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer
The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...
by Jo Cavallo
April 17, 2026
-
5 min
Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape
Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch
April 17, 2026
-
6 min
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...
by ALISON RASH
April 15, 2026
-
8 min